The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa

Trop Med Int Health. 2008 Aug;13(8):1005-15. doi: 10.1111/j.1365-3156.2008.02114.x. Epub 2008 Jul 8.

Abstract

Objective: Estimate the average outpatient cost per patient in care and responding to treatment 1 year after initiation of antiretroviral therapy (ART) under different models of treatment delivery in South Africa.

Methods: At each site, medical records for a sample patients of were reviewed 1 year after ART initiation. Each subject was assigned to one outcome category: in care and responding (IC); in care but not responding (NR); or no longer in care at study site (NIC). Average cost per outcomes category was estimated based on resource utilisation.

Results: Site 1 was an urban public hospital; Site 2 a programme that contracts private general practitioners; Site 3 a rural non-governmental (NGO) AIDS clinic; and Site 4 a peri-urban NGO primary care clinic. At month 12, IC, NR and NIC rates were 67%, 7% and 26% (Site 1); 52%, 3%, and 45% (Site 2); 63%, 9% and 28% (Site 3); and 76%, 11%, and 13% (Site 4). The average outpatient cost per patient initiated was $756 (Site 1), $896 (Site 2), $932 (Site 3) and $1,126 (Site 4). When all costs and all outcomes were taken into account, the average cost to produce an IC patient was $1,128 (Site 1), $1,723 (Site 2), $1,480 (Site 3), and $1,482 (Site 4).

Conclusion: If all ART patients remain in care and responding, total costs will increase but the average cost to produce an IC patient will fall. The cost per ART patient treated varies moderately among sites. Cost differences increase markedly when patient outcomes are taken into account.

Publication types

  • Multicenter Study
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Ambulatory Care / economics
  • Anti-HIV Agents / economics*
  • Anti-HIV Agents / therapeutic use
  • Cost-Benefit Analysis / economics
  • HIV Infections / drug therapy
  • HIV Infections / economics*
  • Health Care Costs
  • Humans
  • Outpatients
  • South Africa

Substances

  • Anti-HIV Agents